Mar 2, 2026 07:00AM
Feb 12, 2026 07:00AM
Feb 12, 2026 07:00AM
Dec 17, 2025 07:02AM
Dec 17, 2025 07:00AM
Nov 10, 2025 07:00AM
Oct 17, 2025 10:00AM DATROWAY plus rilvegostomig shows tumor responses in urothelial cancer trial
Oct 17, 2025 10:00AM
Oct 13, 2025 07:00AM
Oct 13, 2025 07:00AM
Aug 6, 2025 07:00AM
Jul 21, 2025 07:00AM
Jun 9, 2025 08:00AM
Jun 1, 2025 09:00AM DATROWAY® Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer
May 19, 2025 07:00AM
May 13, 2025 07:04AM
May 13, 2025 07:00AM
Mar 4, 2025 07:00AM
Feb 26, 2025 07:00AM
Jan 30, 2025 11:00PM
Jan 8, 2025 07:00AM Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors
Nov 27, 2024 07:03AM
Nov 27, 2024 07:00AM
Nov 12, 2024 07:00AM
Nov 11, 2024 07:00AM
Nov 5, 2024 09:00AM
Oct 29, 2024 07:00AM
Oct 7, 2024 07:00AM Compugen to Present New Clinical Data at SITC 2024
Sep 9, 2024 07:00AM
Aug 29, 2024 07:00AM
Aug 6, 2024 07:00AM
Jul 29, 2024 07:00AM
Mar 5, 2024 07:00AM
Dec 19, 2023 07:01AM
Dec 19, 2023 07:00AM Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
Nov 6, 2023 07:05AM
Nov 6, 2023 07:00AM
Feb 27, 2023 07:00AM
Feb 14, 2023 07:00AM
Dec 6, 2022 07:00AM
Dec 1, 2022 07:09AM
Dec 1, 2022 07:00AM Compugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Anti-Tumor Activity and Immune Activation in Platinum Resistant Ovarian Cancer Patients
Nov 7, 2022 08:05AM
Nov 7, 2022 08:04AM
Nov 7, 2022 08:00AM
Nov 7, 2022 08:00AM
May 11, 2022 06:45AM
Feb 24, 2022 07:19AM
Feb 24, 2022 07:05AM Compugen Announces Appointment of Dr. Mathias Hukkelhoven to its Board of Directors
Feb 24, 2022 07:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All